Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Ramucirumab (RAM) plus paclitaxel (PTX) therapy has shown promising results as a standard second-line treatment for advanced gastric cancer patients. Recently, combined docetaxel (DOC) plus S-1 (DS) therapy could be regarded as the new standard adjuvant chemotherapy for patients with curatively resected stage III gastric cancer. However, the efficacy and safety of RAM plus PTX therapy in patients treated previously with DOC-containing therapy remains unclear.

Methods

This study assessed the clinical outcomes of RAM plus PTX therapy in advanced gastric cancer patients with or without a previous history of treatment with a DOC-containing regimen.

Results

In a series of 107 consecutive patients enrolled for this study, the median PFS and OS were 4.2 and 6.2 months, respectively. Fifty-five patients had a history of prior therapy with DOC and 52 did not. There was no significant difference between with and without DOC groups in the ORR (22.2% vs. 23.5%), PFS (4.2 vs. 5.3 months), or OS (7.2 vs. 6.4 months). In a comparison taking into account the interval from the DOC-containing therapy to the RAM plus PTX therapy, the number of treatment courses was significantly smaller and the PFS significantly shorter in the patient group with an interval of ≤ 6 months (median, 2 vs 4.5 courses, P = 0.033; 3.4 months vs. 5.1 months, P = 0.043).

Conclusions

RAM plus PTX therapy in patients with advanced gastric cancer is effective even in patients who have previously received DOC-containing chemotherapy, especially if the interval is > 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL et al (2012) Global cancer statistics. Cancer J Clin 65:87–108

    Article  Google Scholar 

  2. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med 357:1810–1820

    Article  CAS  Google Scholar 

  3. Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393

    Article  CAS  Google Scholar 

  4. Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guideline 2014 (ver.4). Gastric Cancer 20:1–19

    Article  Google Scholar 

  5. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  CAS  Google Scholar 

  6. Koizumi W, Narahara H, Hata T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    Article  CAS  Google Scholar 

  7. Wilke H, Muro K, Van Cutsem CE et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol 15:1224–1235

    Article  CAS  Google Scholar 

  8. Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesohageal junction adenocarcinoma (REGERD): an international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39

    Article  CAS  Google Scholar 

  9. Shitara K, Muro K, Shimada Y et al (2016) Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19:927–938

    Article  CAS  Google Scholar 

  10. Jung M, Ryu MH, Oh DY et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21:819–830

    Article  CAS  Google Scholar 

  11. Muro K, Oh SC, Shimada Y et al (2016) Subgroup analysis of East Asians in RAINBOW: a phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. J Gastroenterol Hepatol 31:581–589

    Article  CAS  Google Scholar 

  12. Murahashi S, Takahari D, Wakatsuki T et al (2018) A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int J Clin Oncol 23:92–97

    Article  CAS  Google Scholar 

  13. Yoshida K, Kodera Y, Kochi M et al (2020) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patints with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J clin Oncol 37:1296–1304

    Article  Google Scholar 

  14. Migita K, Nashimoto A, Yabusaki H et al (2016) Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol 21:102–109

    Article  CAS  Google Scholar 

  15. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v4.02. (2009) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed Jan 2020

  16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RESIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  Google Scholar 

  17. Valero V, Jones SE, Von Hoff DD et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362–3368

    Article  CAS  Google Scholar 

  18. Sella A, Yarom N, Zisman A et al (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76:442–446

    Article  CAS  Google Scholar 

  19. Kondoh C, Takahari D, Shitara K et al (2012) Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer. Jpn J Cancer Chemother 39:1511–1515

    CAS  Google Scholar 

  20. Shimura T, Kitagawa M, Yamada T et al (2012) The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer. Onkologie 35:176–183

    Article  CAS  Google Scholar 

  21. Ando T, Hosokawa A, Kajiura S et al (2012) Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer 15:427–432

    Article  CAS  Google Scholar 

  22. Yamada Y, Boku N, Mizusawa J et al (2019) Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): An open-label, phase 3, randomized controlled trial. Lancet Gastroenterol Hepatol 4:501–510

    Article  Google Scholar 

  23. Nishikawa K, Tsuburaya A, Yoshikawa T et al (2018) A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-1 trial. Gastric Cancer 21:811–818

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Niigata Cancer Center Hospital, 1-757 Asahimachi-dori, Niigata City, 951-8510, Japan

    Tomoyuki Kakuta, Hiroshi Yabusaki, Takeo Bamba, Masaki Aizawa, Hitoshi Nogami, Tatsuya Nomura, Atsushi Matsuki, Satoshi Maruyama, Yasumasa Takii & Satoru Nakagawa

Authors
  1. Tomoyuki Kakuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Yabusaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Bamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaki Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hitoshi Nogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tatsuya Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Matsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasumasa Takii
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Satoru Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoyuki Kakuta.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kakuta, T., Yabusaki, H., Bamba, T. et al. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy. Int J Clin Oncol 26, 684–693 (2021). https://doi.org/10.1007/s10147-020-01845-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-020-01845-0

Keywords

Search

Navigation